First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

NCT06877650 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

436

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignant Tumors

Interventions

DRUG: JMT108
DRUG: Pembrolizumab
DRUG: Ivonescimab

Sponsor

Shanghai JMT-Bio Inc.